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We were hoping 
to have the 
survey results available for this issue of 
the newsletter. Unfortunately, the final 
summary findings have not been 
completed. Preliminarily, I can report 
that the overall. response rate was 
approximately 20% with most 
characterizing their relationships 
favorably. A good working 
relationship was characterized as 
physicians and hospital working in a 
cooperative way to achieve mutual 
goals with honest and open two-way 
communication and mutual trust and 
respect. The themes of open 
communication and reward and 
recognition of physicians' efforts and 
contributions were at least part of the 
answers to many of the questions in the 
survey. We hope by the next 
newsletter to have a more formal 
report for you. 
I wish to express my sincere thanks to 
all of you for the opportunity to serve 
in this position. With the high caliber 
physicians on our medical staff being 
given opportunities to maximize their 
potential, I believe we will continue to 
grow and function as professionals in 
the highest sense of that term. John 
Castaldo represents us well in this 
sense of professionalism as we 
continue to strive to offer the best 
possible healthcare for our community. 
Happy Holidays to All. Best Wishes 
for the New Year. 
Jo~dio, M.D. 
President, Medical Staff 
Happy 
Holidays! 
Plastic and Reconstructive Surgeon to Serve as 
President-Elect 
Robert X. Murphy, Jr., M.D., 
plastic and reconstructive surgeon, was 
recently nominated and elected to serve 
as Medical Staff President -elect for a 
two-year term beginning January 1, 
1995. 
Dr. Murphy joined the Medical Staff in 
1989, and is a member of the 
Department of Surgery, Division of 
Plastic and Reconstructive 
Surgery /Trauma, Section of Bums. 
A graduate of New York University, 
New York, N.Y., Dr. Murphy 
completed a general surgery internship 
followed by a two-year general surgery 
junior residency at Beth Israel 
Hospital, Boston, Mass. He then 
completed one year of general surgery 
training at Morristown Memorial 
Hospital, Morristown, N.J. Dr. 
Murphy then completed a two-year 
plastic and reconstructive surgery 
residency at Montefiore Medical 
Center and Albert Einstein College of 
Medicine, Bronx, N.Y., followed by a 
clinical fellowship in hand surgery at 
Bellevue Hospital and New York 
University Medical Center, New York, 
N.Y. 
Dr. Murphy is certified by the 
American Board of Plastic Surgery 
with certification of Added 
Qualification in Surgery of the Hand. 
Dr. Murphy is a member of Plastic 
Surgeons Professional Group, Inc., 
located at 1230 S. Cedar Crest 
Boulevard, Allentown. 
At-Large Member Needed for Medical Executive 
Committee 
As a result of the election of Robert X. 
Murphy, M.D., as President-elect of 
the Medical Staff, an at-large seat has 
become vacant on the Medical 
Executive Committee. 
Nominations to fill this seat (with a 
term from March, 1995 through June 
30, 1996) should be submitted in 
writing to John E. Castaldo, M.D., 
Chairman of the Nominating 
Committee, via the Medical Staff 
Services Office, Cedar Crest & I-78, 
or verbally to Joseph A. Candio, 
M.D., Medical Staff President; or 
John W. Hart, Vice President. All 
nominations must be submitted prior to 
March 1, 1995. 
If you have any questions regarding 
this is::ue, please contact Dr. Castaldo 
or Mr. Hart at 402-8900. 
.· 
Mark your calendar! . The next 
Physician Recognition Dinner will be 
held.onSaturday,April1, 1995, at 
the Holiday Inn Conference Center in 
Fogelsville. More info to come. 
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New Am~ulatory Surgery Unit to Open at 
17th & Chew 
Following over a year of planning and 
construction, the hospital's new 
Ambulatory Surgery Unit is scheduled 
to open on January 9, 1995 at 17th & 
Chew. 
The Lehigh Valley Hospital 
Ambulatory Surgery Unit, which will 
be located on the second floor, is 
dedicated to providing cost-efficient, 
patient focused care, and will include 
the following areas: 
• A decentralized registration area to 
expedite patient registration. 
• A unit specific centralized 
documentation processing area to 
assure chart document preparation and 
processing. 
• Pre-admission testing, which is 
currentlylocated in Suite ill of 401 
N. 17th Street, will move adjacent to 
the unit. This will offer expanded 
appointment scheduling which will be 
completed at the time of OR 
scheduling. Pre-admission processing 
visits will be scheduled for all 
ambulatory surgery patients to provide 
the time for an anesthesia visit and 
avoid delay on the day of procedure. 
For the convenience of your patients, 
unscheduled visits to pre-admission 
processing will be accommodated by 
contacting the scheduling department. 
• Staging and recovery areas (24) for 
pre- and post-:-procedure care of 
patients. 
• Pediatric staging and recovery areas. 
(Pediatric outpatients scheduled for 
ambulatory surgery will continue to be 
staged pre- and post-procedure in the 
pediatric unit on the 5th floor.) 
• Operating room suite consisting of 
eight operating rooms and a 
urodynamics suite. · 
• Two minor procedure rooms. 
• A 13-bay Post Anesthesia Care 
Area. 
Packets including information about the 
new Ambulatory Surgery Unit will be 
distributed to physicians' offices prior 
to the opening of the new unit. 
PLEASE NOTE: Outpatient G .I. lab 
procedures, myelograms, arteriograms, 
and lithotripsy procedures will continue 
to be performed at Cedar Crest & I-78. 
These cases will be scheduled through 
centralized scheduling, and the patient 
will be staged pre- and post-procedure 
through 4B and 5B, respectively. 
If you have any questions regarding the 
new Ambulatory Surgery Unit, please 
contact Barbara Frantz, Director, 
Ambulatory Surgery Unit Staging/ 
PAP/PACU, at 402-8599 or Virginia 
Kovalovich, Director, Ambulatory 
Surgery Unit OR, at beeper 1052. 
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Senior Vice President of Clinical Services Announced 
Robert J. Laskowski, M.D., formerly 
of Farmington, Conn., has been named 
Senior Vice President of Clinical 
Services, a new position at Lehigh 
Valley Hospital, effective January 
1995. In his position, Dr. Laskowski 
will coordinate the activities of the 
hospital's clinical departments, assure 
the delivery of medical services follows 
established procedures, and oversee 
medical education and quality 
assurance programs. 
Dr. Laskowski was previously group 
medical director and president, 
Northeast Permanente Medical Group, 
Farmington, and a member of the 
medical faculty at the University of 
Connecticut. He had also served as the 
group's associate regional medical 
director and vice president. 
Dr. Laskowski earned his bachelor's 
degree, summa cum laude, medical 
degree, and M.B.A. from the 
University of Pennsylvania. He 
completed an Internal Medicine 
residency at the University of Chicago 
Hospitals and Clinics, and a fellowship 
in General Internal Medicine at the 
Hospital of the University of 
Pennsylvania. He was a Robert Wood 
Johnson Foundation ·Clinical Scholar at 
the University of Pennsylvania, 1981 to . 
1983. 
Dr. Laskowski is certified in Internal 
Medicine with added qualifications in 
Geriatric Medicine by the American 
Board of Internal Medicine. He is a 
member of the American College of 
Physicians, the American Medical 
Association, the Society for General 
Internal Medicine, the American 
Geriatrics Society, the Gerontological 
Society of America, the American 
College of Physician Executives, and 
the American Public Health 
Association. 
Administrator for Skilled Nursing Facility Named 
Terry C. Tressler, of Sewell, N.J., has 
been named administrator for Lehigh 
Valley Hospital's skilled nursing unit at 
17th & Chew. In this newly created 
position, he will be responsible for 
managing all of the activities of the 
new 52-bed sub-acute care facility. 
The unit will give short-term care to 
patients who are medically stable but 
not well enough to be discharged or 
transferred to another facility. The 
hospital received approval for the 
project this past summer and plans to 
begin operations in February, 1995. 
Since 1979, Mr. Tressler has served in 
administrative positions at nursing and 
retirement centers in Philadelphia and 
southern New Jersey. Most recently, 
he was administrator of Bala Nursing 
and Retirement Center, a 180-bed 
facility in Philadelphia. 
Mr. Tressler earned a law degree from 
Temple University School of Law. He 
received a master's in public 
administration and a bachelor's in 
health planning and administration 
from Pennsylvania State University. 
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Vice President of Public Affairs Named 
Mary Alice Czerwonka, former 
director of Corporate Communications 
for the Fairview Health System, 
Minneapolis, Minn., was recently 
named Vice President of Public Affairs 
at Lehigh Valley Hospital. 
In this position, Mrs. Czerwonka will 
be responsible for planning and 
overseeing the implementation the 
hospital's internal and external public 
relations strategies. 
Prior to her position with the Fairview 
Health System, Mrs. Czerwonka held 
public relations management posts at 
the Ramsey Clinic/St. Paul Ramsey 
Medical Center, St. Paul. She also 
served as a reporter and editor for The 
Times, Hammond, Ind. 
Mrs. Czerwonka earned a bachelor's 
degree in journalism from Indiana 
University, Bloomi.Iigton, Ind. She 
was a board member of the American 
Society for Health Care Marketing and 
Public Relations and is an Accredited 
Business Communicator and member 
of the Accreditation Board of the 
International Association of Business 
Communicators. 
ABC News' 20/20 Films Stroke Surgery Story at 
Lehigh Valley Hospital 
National network television recently 
turned its spotlight on Lehigh Valley 
Hospital. ABC News' 20/20 
Magazine program chose the hospital 
as the focus of a story about the results 
of a national research study. The trial 
found that surgery is the best medicine 
for preventing strokes in persons who 
have blocked carotid arteries but no 
related symptoms. 
During five days of filming at the 
hospital, nearly 15 hours of interviews, 
surgeries, patient exams, and 
diagnostic tests were captured on video 
tape. Often starting before sunrise and 
lasting until after dark, a cameraman, 
sound technician, and two producers 
from 20/20's medical branch pursued 
doctors, patients, nurses, and other 
professionals in search of yet another 
image or sound bite to take back to the 
editing room in Boston where the 
segment will be assembled. 
According to producer, Roger Sergei, 
the story will be aired in early January 
in 20/20's regular Friday night slot, 10 
to 11 p.m. About 85 percent of the 10 
to 12 minute piece will feature scenes 
shot at Lehigh Valley Hospital. 
Lehigh Valley Hospital was chosen as 
the site for filming because of its 
strong track record in recruiting 
patients for the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). This 
study compared surgery with medicine 
in treating persons with major carotid 
artery blockage. 
Continued on Page 6 
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Lehigh Valley Hospital recruited more 
patients-- 142 --than any of the other 
39 participating hospitals, and the 
efforts of the hospital's principal 
investigator, John E. Castaldo, M.D., 
stood above those of the rest 
throughout the United States and 
Canada. 
Highlighting the filming was an hour-
long· interview between Dr. Timothy 
Johnson, 20/20's easy-to-spot medical 
editor/host, and Dr. Castaldo. 
Medical Staff/Administrative Exchange Sessions 
On November 10, the first Medical 
Staff/ Administrative Exchange Session 
was held in an attempt to encourage 
the mutual exchange of information 
between members of the Medical Staff 
and senior management in an informal, 
relaxed atmosphere. 
Due to the apparent success of the first 
session, beginning in January, Medical 
Staff/ Administrative Exchange Sessions 
will be held on a regular basis. Listed 
below are the dates for the Exchange 
Sessions for 1995: 
January 19, February 16, March 16, 
April 20, May 18, June 15, July 20, 
August 17, September 21, October 
19, November 16, and December 21. 
All sessions will be held in Conference 
Room 1, Side B of the John and 
Dorothy Morgan Cancer Center, from 
5:30 to 7:30 p.m. As space is limited 
to 40 people, registration will be taken 
on a first-come, first-serve basis. 
Part of each session will be dedicated 
to answering questions. In order to 
have an opportunity to thoroughly 
research questions, we ask that they be 
submitted in advance. 
For more information or to register for 
any of the above sessions, please 
contact Janet M. Seifert in Physician 
Relations at 402-9853. 
TV Remote . Control Units Installed at Cedar Crest 
New televisions with remote control 
units have been installed in patient 
rooms at Cedar Crest & I-78. The 
remote is cable mounted to the wall at 
the head end of the patient's bed. 
On several occasions, hazardous 
conditions have occurred as a result of 
melted remotes being placed on the 
overbed light fixture. As a safety 
reminder, please remember that these 
light fixtures get extremely hot and that 
nothing is to be placed on them. 
Your attention to this matter is 
appreciated. 
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Cancer Staging Forms 
During the last year, the Cancer 
Committee has worked with the 
Medical Records Department to 
develop a process that will ensure the 
accrual staging of cancer. Staging 
forms along with the proper usage of 
these forms was developed and 
approved by the Cancer Committee, 
Medical Records Committee, and 
Medical Executive Committee. 
The process will be implemented on 
January 9, 1995, and will be managed 
in the following way: 
• Pathology will attach the site 
specific staging form to the positive 
pathology report. 
• A pathologist will check/ complete 
and sign the histopathologic 
classification form. 
• The attending physician will 
check/ complete and sign the clinical 
classification and staging form. 
• Medical Records Department, during 
post discharge chart analysis, will 
verify the presence of a staging form 
on charts containing a cancer diagnosis 
and/ or positive pathology report. 
• Missing forms will be placed on the 
chart by a Tumor Registrar. 
• Charts with missing staging forms 
will be flagged as deficient and 
managed by the Medical Records 
Department as other deficiencies. 
By managing the staging of cancer in 
this manner, Lehigh Valley Hospital 
will be able to compare its experience 
to that of other facilities, be prepared 
for a soon-to-be implemented JCAHO 
requirement, and most importantly, 
enhance the care and treatment of the 
patient with cancer. 
If you have any questions about this 
issue, please contact Sue Cassium in 
the Medical Records Department at 
402-4451, or Andrea Geshan, Tumor 
Registry, and 402-0526. 
Neutropenic Patient Accommodations 
Patient care accommodations for the 
neutropenic/immunosuppressed patient 
were recently evaluated by David 
Prager, M.D., chief, Division of 
Hematology/Medical Oncology, Luther 
V. Rhodes ill, M.D., chief, Division 
of Infectious Diseases, and Irene 
Ehrgott, Oncology Clinical Nurse 
Specialist. In the past, the practice at 
Lehigh Valley Hospital was to place 
the immunosuppressed and/or 
neutropenic patient in a semi-private 
room without a roommate. Concern 
for appropriate bed utilization 
prompted a survey of 10 of the 50 
leading cancer centers to determine 
alternate standards of care for the 
immunosuppressed patient. 
As a result of the benchmarking 
survey, literature review and physician 
input, the following. changes to our 
patient accommodations were initiated 
as of October 21, 1994: 
Continued on Page 8 
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The immunosuppressed and/or 
neutropenic patient may be placed in a 
semi-private room with a roommate. 
Recommendations for the care of the 
immunosuppressed/neutropenic patient 
are as follows: 
• Roommates of neutropenic patients 
will be screened daily by the nursing 
staff for: 
o Open draining wounds not 
covered by dressing due to 
wound size or location. 
o Contagious infectious 
diseases such as disseminated 
varicella zoster, herpes simplex, 
tuberculosis, measles, mumps, 
influenza, infectious diarrhea 
(only if patient has poor 
hygiene or is confused), 
pneumonia (only if due to TB 
or staph aureus). 
o Live viral vaccines for 
measles, mumps, rubella or oral 
polio vaccine given within two 
months. 
• Both staff and visitors must wash 
their hands using disinfectant soap 
upon entering and leaving the patient's 
room. 
• Visitors will be screened the same as 
patient's roommates. 
• Visiting guidelines will be 
emphasized and discussed with ALL 
PATIENTS, including family. Limit 
2-3 visitors at a time. 
The following outcomes will be 
monitored for one year: 
• Increase or decrease of infection rate 
for the immunosuppressed and/or 
neutropenic patient. 
• Compliance of handwashing for staff 
and visitors. 
• Compliance with requirements of 
screening for roommates and visitors. 
• Bed utilization. 
• Fiscal aspects. 
Visitors will also be provided with 
guidelines regarding precautions for 
patients with low white blood cell 
counts. 
If you have questions or need . 
additional information, please contact 
Dr. Rhodes at 402-8438, or Mrs. 
Ehrgott at beeper 1500. 
;:;~-~~~11~1~~~~····! 






Department has begun its Respiratory 
Virus Surveillance program for the 
1994-1995 flu season. The value of 
the surveillance program is to alert the 
medical staff and other physicians 
which viruses are circulating within the 
community in order to ensure 
appropriate immunization of their 
patients and to activate preventive 
measure to protect those for whom 
respiratory viral infections may be life 
threatening. 
Last year's predominate isolate was A-
Beijing. This year's vaccine contains 
B-Panama, A-Texas, and A-
Shangdong. No isolates have been 
recovered in Pennsylvania to date. 
Mic~biology/Virology will supply 
spectmen collection kits consisting of a 
sterile container with phosphate buffer 
saline to gargle, a tube of viral 
tran~rt media, case history form, and 
a climcallaboratory requisition form. 
To collect the specimen: 
• The specimen should be collected 
within two days and no later than three 
days from the onset of respiratory or 
flu-like symptoms. 
• Gargle with sterile saline into 
container. 
• Spit saline back into container. 
~ Pour saline throat washing directly 
mto the tube of pink fluid. 
• Label tube with patient's name, date, 
and location, and place on wet ice. 
• Complete Virology History form 
which is included in plastic pouch. 
• Complete the Clinical Laboratory 
Requisition Form for each patient's 
specimen for outside accounts. 
Specimens from patients seen in the 
Emergency Departments will be 
ordered through Phamis with the test 
code "!NFL" for an-Influenza A/B 
screen or "RVCU" for a complete 
Respiratory Virus study. (Outside 
accounts, please specify if just an 
influenza screen is wanted.) The cost 
of an Influenza Screen is $50, and the 
cost for a full respiratory virus workup 
is $85. 
• Specimens from the Emergency 
Departments should be hand delivered 
to Microbiology on wet ice. 
Specimens from outside accounts 
should be refrigerated until courier 
pick-up and should be transported on 
wet ice. 
Once the specimen is received in the 
laboratory, it will be tested for 
Influenza A and B (and other viruses 
requested). Positive results will be 
phoned. Final reports will be issued as 
soon as the isolate is identified or when 
the specimen is determined to be 
negative. (Five days for Influenza 
Screen, two weeks for complete 
respiratory virus culture.) 
For more information or to obtain 
collection kits, please contact 




• WluJt's New at 17th & Chew 
.. 
Gompel. Pathology in Gynecology 
and Obstetrics. 4th ed. Lippincott, 
1994. 
Piper. Motor Assessment of the 
Developing Infant. Saunders, 1994. 
Aquilera. Crisis Intervention. 7th ed. 
Mosby, 1993. 
Okeson. Management of 
Temporomandibular Disorders and 
Occlusion. 3rd ed. Mosby, 1993. 
Donnez. Atlas of Laser Operative 
Laparoscopy and Hysteroscopy. 
Parthenon, 1994. 
• WluJt's New at Cedar Crest & 1-78 
The Official ABMS Directory of 
Board Certified Medical Specialists. 
27th ed. Marquis Who's Who, 1995. 
News from Research 
A call for abstracts has been issued by 
the following organizations: 
The American College of Surgeons 
80th Annual. Clinical Congress to be 
held in New Orleans, La., on October 
22, 1995. Submission due date is 
March 31. 
The American Diabetes Association 
55th Annual Meeting Scientific 
Sessions to be held in Atlanta, Ga., on 
June 10, 1995. Submission due date is 
January 6. 
The American Psychiatric Association 
Annual Meeting to be held in Miami 
Beach, Fla., on May 20, 1995. 
Submission due date is January 15. 
Fogelman. An Atlas of Clinical 
Nuclear Medicine. 2d ed. Mosby, 
1993. 
Socioeconomic Characteristics of 
Medical Practice. AMA, 1994 (1982-
1993 data) 
Froelicher. Manual of Exercise 
Testing. 2d ed. Mosby, 1994. 
• library Trivill 
Most/lease expensive books purchased 
during 1994: 
Haubrich. Bockus-Gastroenterology. 
5th ed. Saunders, 1995. 4 vol. set-
$635.00. 
Conover. Pocketguide to Electro-
cardiography. 3rd ed. Mosby, 1994. 
$19.95. 
The American Society of Plastic and 
Reconstructive Surgery Annual 
Meeting to be held in Montreal, 
Canada, on October 7, 1995. 
Submission due date is February 22. 
The Society for Pediatric Research 
Annual Meeting to be held in San 
Diego, Calif. on May 8, 1995. 
Submission due date is January 4. 
The Society of Nuclear Medicine 
Annual Meeting to be held in 
Minneapolis, Minn., on June 12, 1995. 
Submission due date is January 4. 
For instructions, forms, and further 
information, please contact Kathleen 




Broce R. Ganey, D.P.M., podiatrist, 
was recently notified by the American 
Board of Podiatric Orthopedics and 
Primary Podiatric Medicine that he 
successfully completed the certification 
examination and is now a Diplomate of 
the Board in that section. 
Papers, Publications and Presentations 
Members of the hospital's staff 
recently presented a poster, 
Microalbuminuria: A Positive 
Predictive Value for Coronary Heart 
Disease?, at the American Society of 
Nephrologists National Meeting held in 
Orlando, Fla. Those involved in the 
poster presentation included: David 
del Rosario, M.D., medical resident; 
Mary Ann Gergits, R.N., research 
nurse; Nelson P. Kopyt, D.O., 
nephrologist; Carolyn Peters, R.N., 
3C; and James F. Reed, Ph.D., 
Director of Research. 
James W. Jaffe, M.D., chief, Section 
of Cardiovascular/Interventional 
Radiology, will present two papers at 
the Annual Meeting of the Society of 
Cardiovascular and lnterventional 
Radiology to be held on March 27, 
1995 in Ft. Lauderdale, Fla. The 
papers are titled Treatment of 
Symptomatic Lower Extremity Deep 
Venous Thrombosis with Retrograde 
Catheter Placement and Urokinase 
Infusion and Assessment of Venous. 
Valvular Damage after Retrograde 
Venous Passage of a Catheter-
Guidewire Infusion System. 
Peter A. Keblish, M.D., chief, 
Division of Orthopedic Surgery, was a 
member of the faculty in a recent 
symposium, Revision Hip and Knee 
Surgery: The Cost Equation, held in 
Scottsdale, Ariz. Dr. Keblish 
presented papers on three topics, 
namely, Surgical Approaches for the 
Stiff Knee in Revision Total Knee 
Arthroplasty, Bone Graft Options, 
and Treatment of the Infected Total 
Knee Arthroplasty. He also served 
on the discussion panels and directed a 
workshop on Revision Total Knee 
Replacement. The symposium was 
directed at both the academic and 
economic ramifications of the costly 
subject of Total Joint Revisions. 
Stephen K. Klasko, M.D., vice chair 
and residency program director, 
Department of Obstetrics and 
Gynecology, was recently informed 
that his abstract, Psychologic Effects 
of Hysterectomy - Development of a 
Biopsychosocial Model, has been 
accepted for poster presentation at the 
23rd Annual Meeting of the American 
Society for Psychosomatic Obstetrics 
and Gynecology to be held February 
23-25, 1995 in Virginia. 
Continued on Page 12 
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Yasin Khan, M.D., anesthesiologist, 
presented four poster abstracts at the 
American Pain Society Annual Meeting 
held recently in Miami, Fla. 
The poster abstracts included: Trial 
Percutaneous Peripheral Nerve 
Stimulation (PNS): A Technique to 
Determine Efficacy Prior to Implant; 
Is Percutaneous Spinal Cord 
Stimulation Cost Effective for the 
Treatment of Pain Dysfunctional 
Syndrome Compared to Epidural 
Infusions?; Spinal Cord Stimulation 
for Atypical Facial Pain and 
Trigeminal Neuralgia; and Use of 
Spinal Cord Stimulator for Chronic 
Pancreatitis. 
Steven J. Lawrence, M.D., 
orthopedic surgeon, recently authored 
an article, The Sural Nerve in the 
Foot and Ankle: An Anatomic Study 
with Clinical Surgical Implications. 
The article was published in the 
September, 1994 edition of Foot & 
Ankle lntei7Uitional. 
Thomas D. Meade, M.D., orthopedic 
surgeon, moderated the Healthy Heart 
program at Muhlenberg College on 
November 14. 
Upcoming Seminars, Conferences and Meetings 
Regional Symposium 
Series VI 
Endocrinology Update will be held on 
Saturday, January 14, 1995, from 7:30 
a.m. to 12:30 p.m., in the Auditorium 
of Lehigh Valley Hospital, Cedar Crest 
& I-78. 
Physicians, nurses, and other health 
professionals interested in an update in 
endocrinology will benefit from this 
program. 
At the completion of this program, the 
participant should be able to: 
• clinically differentiate and institute 
initial workup for androgen problems 
• select an appropriate treatment 
program for a specified type of 
osteoporosis 
• explain. the presence of several 
thyroiditis conditions and describe their 
long term clinical course 
• discuss the current theory of insulin 
resistance and how it relates to disease 
states and treatment 
• describe those patients with 
hypertension who may have a 
remediable endocrine cause. 
Sixth Annual Symposium in 
Geriatrics will be held on Saturday, 
January 28, from 8 a.m. to 3 p.m., in 
the Auditorium of Lehigh Valley 
Hospital, Cedar Crest & I-78. 
Physicians, nurses, medical residents, 
pharmacists, social workers, and other 
health professionals interested in an 
update in geriatrics will benefit· from 
the program. 
Continued on Page 13 
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At the completion of this program, 
participants should be able to: 
• identify current approaches to the 
care of the elderly including treatment 
for osteoporosis and benefits of 
geriatric research 
• identify the impact of 
pharmacokinetic and pharmacodynamic 
changes in the elderly on drug therapy 
compliance and apply strategies to 
prevent or minimize adverse treatment 
outcomes 
• identify and incorporate a variety of 
community resources and placement 
options for elderly patients and their 
caregivers 
• describe the changes in the eye 
which occur with aging and 
differentiate normal changes from 
disease process . 
• identify common causes of urinary 
incontinence, describe factors affecting 
continence, and identify three 
approaches to the management of 
urinary incontinence in the elderly. 
For more information on the above 
programs, please contact Human 
Resource Development at 402-1210. 
Primary Care Seminar 
Otitis Media will be presented by 
Charles F. Smith, M.D., on 
Wednesday, December 21, from 10 
a.m. to noon, in the Auditorium at 
17th & Chew. 
For more information, contact Karen 
Nodoline in the Department of Family 
Practice at 402-4950. 
Psychiatry Grand 
Rounds 
Rochester Capitation Program for 
the Mentally m will be presented by 
Sylvia K. Reed, Ph.D., Project 
Director, Management Information 
Systems, Department of Psychiatry, 
University of Rochester Medical 
Center, and Ethel Davis Jackson, 
Associate Commissioner for Adult 
Services, New York State Office of 
Mental Health, on Thursday, January 
19, from noon to 1 p.m., in the 
Auditorium at 17th & Chew. 
As lunch will be provided, pre-
registration is requested. For more 
information or to register, contact Lisa 
Frick in the Department of Psychiatry 
at 402-2810. 
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• Wanted -- M~(:lical Director, 
Skilled Nursing Facility, Lehigh 
Valley Hospital, 17th & Chew--
Primary care physician sought as 
Medical Director for Lehigh Valley 
Hospital's hospital-based, interim 
care skilled nursing facility. Will 
oversee operations of new 52-bed 
unit and participate in medical 
management of patients. Board 
certification required. Experience 
working in skilled nursing facility 
preferred. Position is part-time (.25 
FTEl. Interested candidates please 
send CV, in confidence, to Francis 
Salerno, M.D., Chair, Search 
Committee, c/o Carol Voorhees, 
Physician Recruitment Department, 
1243 S. Cedar Crest Boulevard, 
Allentown, PA 18103, 402-3090, 
fax- 402-9858. 
• For Sale or Lease -- Springhouse 
Professional Center, 1575 Pond 
Road. Ideal for physician's office. 
Approximately 2,500 sq. ft. 
• For Sale -- Office building at 
Northeast corner of 19th and Turner 
Streets in Allentown. Upper level -
2,400 + sq. ft., large waiting room, 
two large consultation rooms, five 
exam rooms, etc. Lower level-
2,300 + sq. ft. Parking lot for 16 
cars. 
• For Sale -- Medical office suite in 
the 1230 S. Cedar Crest Boulevard 
Medical Office Building. 1 ,225 sq. 
ft. 
• For Lease -- Office to sublet on 
Monday, Tuesday, Thursday, and 
Friday. 950 sq. ft. Common 
waiting area. Lakeside Professional 
Building, Quakertown. 
• For Lease -- Slots are currently 
available for the Brown Bag suite at 
Kutztown Professional Center. Ideal 
for satellite location. 
• For Lease -- Several time slots are 
available in the medical office 
building on the campus of Gnaden 
Huetten Memorial Hospital in 
Lehighton. 
• For Lease -- Medical-professional 
office space located on Route 222 
in Wescosville. Two 1,000 sq. ft. 
offices available or combine to form 
larger suite. 
• For Lease -- Medical office space 
located in Peachtree Office Plaza in 
Whitehall. One suite with 1 ,500 sq. 
ft. (unfinished - allowance available), 
and one 1,000 sq. ft. finished suite. 
• For Lease -- Specialty practice 
time-share space available in a 
comprehensive health care facility. 
Riverside Professional Center, 401 9 
Wynnewood Drive, Laurys Station. 
Half- or full-day slots immediately 
available. 
• For Lease -- Professional office 
space available in an established 
psychology and psychotherapy 
practice at 45 N. 13th Street, 
Allentown. Large, warm Victorian 
building in a relaxed atmosphere. 
Secretary and billing available and 
included in some leases. Furnished 
or unfurnished full offices and 
sublets available. Utilities included. 
For more information or for 
assistance in finding appropriate 
office space to meet your needs, 
contact Janet M. Seifert, Physician 




The Who's New section of Medical 
Stoff Progress Notes contains an 
update of new appointments, address 
changes, newly approved privileges, 
etc. Please remember that each 
department or unit is responsible for 
updating its directory, rolodexes, and 
approved privilege rosters. 
Medical Staff 
Appointments 
Robert H. Schmidt, DO 
(solo) 
1227 Liberty Street 
Suite 303 
Allentown, PA 18102-2606 
(610) 437-1959 
Department of Family Practice 
Provisional Referring 
Christopher J. Stille, MD 
(Children's Healtb.Care- Dr. Toft) 
Children's Health Care 
Children's HealthCare Center· 
1517 Pond Road 
Allentown, PA 18104-2250 
(610) 395-4444 
Department of Pediatrics 
Division of General Pediatrics 
Provisional Active 
Additional Privileges 
Victor J. Celani, MD 
Department of Surgery 
Division of Vascular Surgery 
Active 
Placement of Transluminal Peripheral 
Arterial Stents 
D. Lynn Morris, MD 
Department of Medicine 
Division of Cardiology 
Coronary Rotoblator Privileges 
Active 
Change of Status 
James R. Clifford, ·MD 
Department of Family Practice 
From Courtesy to Emeritus Courtesy 
LeRoy B. Gerchman, MD 
Department of Family Practice 
From Courtesy to Referring 
Michael J. Kareha, DMD 
Department of Dentistry 
Division of Periodontics 
From Consulting to Referring 
Laura Kramer, DO 
Department of Medicine 
Division of General Internal Medicine 
From Consulting to Referring 
John J. Mecca, MD 
Division of Family Practice 
From Courtesy to Referring 
Lisa H. Medina, MD 
Department of Family Practice 
From Courtesy to Provisional Active 
Howard S. Selden, DDS 
Department of Dentistry 
Division of Endodontics 
From Courtesy to Emeritus Referring 
Kenneth D. Truscott, MD 
Department of Family Practice 
From Courtesy to Referring 
Continued on Page 16 
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Continued from Page 15 
Practice Disassociation 
John A. KibeJstis, MD no longer 
associated with Pulmonary Associates, 
PC 
M. Bruce Viechnicki, MD no longer 
associated with College Heights 
OBGYN Associates, PC 
Address and Telephone 
Number Changes 
John A. Kibelstis, MD 
1251 S. Cedar Crest Blvd. 
Suite 107A 
Allentown, PA 18103 
(610) 435-6502 
Edward A. Schwartz, DPM 
Coordinated Health Systems 
2775 Schoenersville Road 
Bethlehem, PA 18017 
(610) 861-8080, Ext. 250 
FAX: (610) 861-0258 
M. Bruce Viecbnicki, MD 
M. Bruce Viechnicki, MD & 
Associates PC 
3131 College Heights Blvd. 
Allentown, PA 18104 
(610) 366-7000 
Resignations 
lain F. Black, MD 
Department of Pediatrics 
Division of Cardiology 
Consulting 
Norman C. Kramer, MD 
Department of Medicine 
Division of General Internal Medicine 
Emeritus Consulting 
Death 
George E. Moerkirk, MD 
Department of Emergency Medicine 






Deborah R. Miller, PNP 
Physician Extender 
Professional - RN 
(ABC Pediatrics - Dr. Levick) 
Address Change 
Elizabeth M. DelPezzo, PbD 
Park Professional Building 
2200 W. Hamilton Street 
Suite 307 




A Service of lEHWV.AI.LEY 
HOSPITAL 
Autoimmune Thyroid Disease: Highly Sensitive 
Assays for Thyroid Auto-Antibodies 
Thyroglobulin (Tg) is a very large 
molecule produced by the thyroid cells 
and stored in the thyroid colloid. 
Thyroid hormones are synthesized on 
Tg which therefore forms the nidus on 
which the synthesis of T 4 and T3 takes 
place. The enzyme which allows for 
the formation of T4 and T3 is thyroid 
peroxidase (TPO). This has recently 
been verified on the microsomal 
antigen in chronic thyroiditis. 
The measurement of thyroid peroxidase 
(TPO) auto-antibodies used with the 
thyroglobulin antibody (TgAb) test can 
be of considerable value in the 
diagnosis of thyroid diseases such as 
Autoimmune Chronic Thyroiditis 
(Hashimoto's Disease). Complement 
fixing immunoglobulin G polyclonal 
autoantibodies directed against a 
thyroid specific cell surface antigen 
TPO are capable of destroying 
follicular cells. The prevalence of 
TPO antibodies among adults, 
especially women, is approximately 
10% . Some studies of pregnant 
women have reported an incidence of 
positivity as high as 20%. Because of 
this high prevalence for thyroid 
'antibodies, this test has been promoted 
as a primary screening test for 
autoimmune hypothyroidism. Since 
thyroid antibodies are detectable years 
before serum TSH levels become 
elevated, the screening with TPO and 
TgAb may identify a subgroup whose 
TSH levels may require monitoring on 
a yearly basis. Epidemiologic data 
suggests that patients with an increased 
TSH level and normal T4 will progress 
to overt thyroid failure at a rate of 5 % 
per year if they also have increased 
titer of anti-TPO autoantibodies. 
A particular group that would 
especially benefit from the detection of 
thyroid autoantibodies by means of 
these highly sensitive assays are 
pregnant women. During pregnancy 
the presence of thyroid antibodies has 
been correlated with an increased rate 
of miscarriage. 
Following delivery, postpartum 
thyroiditis is a fairly common event 
which causes symptoms in women 
because of hypothyroidism. Studies 
have demonstrated that the prevalence 
of post pactum thyroid disease (PPTD) 
is about 8-10% in the US population in 
the 4-8 month post delivery period. 
Furthermore, almost all such patients 
have anti TPO antibodies detectable 
early in pregnancy and with a post 
partum rise. More than 33% of such 
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anti TPO positive patients develop 
some form of PPI'D, in particular 
those patients with the highest levels of 
thyroid antibodies. 
The indications for ordering these two 
tests anti-TPO autoantibodies and anti-
thyroglobulin antibodies (TgAb) are 
summarized as follows: 
1) TSH elevation of unknown 
etiology. 
2) Goiter of unknown etiology. 
3) Screening for risk of postpartum 
thyroiditis (during pregnancy 
and after delivery. 
4) 
5) 
Familial evaluation for establish 
cause of genetic thyroid disease. 
Risk assessment for the 
development of thyroid 
dysfunction during drug 
treatment (lithium, interferon, 
cytokines). 
6) Evaluation of suspected 
polyglandular autoimmune 
diseases such as pernicious 
anemia, Addison's disease, 
vitiligo, Type I diabetes 
mellitus, and certain hepatic 
disorders as chronic active 
hepatitis and hepatitis C. 
Although somewhat redundant, the 
ordering of both tests is suggested as 
TPO is more sensitive but less specific 
than TgAb. 
Alternatively, Autoimmune thyroid 
disease is also associated with 
stimulating antibodies such as thyroid 
stimulating Immunoglobulin (TSI). 
Studies have shown that TSI is present 
in 80-90% of patients with active 
Grave's disease and absent in patients 
with remission. Measuring TSI is 
helpful in monitoring Grave's disease 
during pregnancy, in post pregnancy 
management and in neonatal Grave's 
disease. 
Gerald E. Clement, Ph.D. 
Technical Director 
Clinical Laboratories 
Larry N. Merkle, M.D. 
Chief, Endocrinology 
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NATIONAL BLOOD RESOURCE EDUCATION PROGRAM'S NATIONAL INSTITUTES OF HEALTH 
National Heart, Lung, and Blood Institute 
TRANSFUSION ALERT 
Indications for the Use of Red Blood Cells, 
Platelets, and. Fresh Frozen Plasma 
Rationale for 
Component Use 
Red Blood Cell 
Transfusion 
Red blood cell (RB() transfu-
sions increase oxygen-carrying 
capacity in anemic patients. Trans-
fusing 1 unit of RBC's will usually 
increase the hemoglobin by about 
1 g/dL and the hematocrit by 2-3 
percentage points in the average 70 
kg adult. 
In deciding whether to transfuse 
a specific patient. the physician 
should consider the age of the 
person; the etiology, degree, and 
Platelet Transfusion 
Platelet transfusions are adminis-
tered to control or prevent bleeding 
associated with deficiencies in 
platelet number or function. One 
unit of platelet concentrate should 
increase the platelet count in the 
average adult recipient by at least 
5,000 platelets/f.lL 
Prophylactic platelet transfusion 
may be indicated to pre-·em bleed-
ing in patients with severe thrombo-
cytopenia. For the clinically stable 
patient with an intact vascular 
system and normal platelet function. 
prophylactic platelet transfusions 
Blnod transfusion can be lifesaving therapy for patients with a 
variety of medical and surgical conditions. Advances in the use of blood • 
components have made whole blood tratzsfusions rarely necessary. Blcod 
component therapy provides better treatment for the patient by giving 
only the specific component needed. Such therapy helps .to conserve 
blood resources because compommtsfrom I unit of blood can be used to 
treat several patients. 
Transfuse 
Red Blood Cells: 
+ Only to increase oxygen-
carrying capacity in anemic 
patients. 
time course of the anemia: hemody-
namic stability; and the presence of 
coexisting cardiac. pulmonary. or 
vascular conditions. There is no 
across-the-board threshold or 
·'trigger .. , Both undertransfusion and 
ovemansfusion should be avoided. 
~'hen a treatable cause of 
anemia can ue identified and time 
Transfuse Platelets: 
+ To control or prevent 
bleeding associated with 
deficiencies in platelet 
number or function. 
may be indicated for platelet counts 
of <10.000-20,000/f.lL. A patient 
undergoing an operation or other 
invasive procedure is unlikely to 
benefit from prophylactic platelet 
transfusions if the platelet count 
is 50.000/f.lL or more and 
thrombocytopenia is the sole 
abnormality. Platelet transfusions at 
higher platelet counts may be 
required for patients with systemic 
Do Not Transfuse 
Red Blood Cells: 
• For volume expansion only 
• In place of a hematinic . 
• To enhance wound healing 
• To improve general ~ell­
being." 
permits. specific therapy (e.g .. ,.itamin 
B ... iron. folate) should be used in 
preference to transfusion. If volume 
expanders are indicated. fluids such 
as crystalloid or nonblood colloid . 
solutions should be administered. 
Do Not Transfuse 
Platelets: 
• To patients with immune or 
thrombotic thrombo-
cytopenic purpura (ITP or 
TIP), unless there is cluti-
cally significant bleeding 
+ Prophylactically with 
massive blood transfusion 
• Prophylactically following 
cardiopulmonary bypass. 
bleeding and for patients at higher 
risk of bleeding because of addi-
tional coagulation defects. sepsis. or 
platelet dysfunction related to 
medication or disease. 
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Fresh Frozen Plasma 
Transfusion 
Fresh frozen plasma ( FFP) 
transfusions should be administered 
only to increase the level of clotting 
f:.~ctors in patients with :1 demon-
strated deficiency. Labor.ltory tests 
should be used to monitor the 
patient with a suspected dotting 
disorder. If prothrombin time (PT) 
and partial thromboplastin time 
< PTT) are <1. 5 times nom1al, FFP 
transfusion is rarely indicated. 
Patients who have been given 
the anticoagulant warfarin sodium 
Risks Common to All 
Blood Components 
Infection and alloimmunization 
are the major complications associ-
ated •vith transfusion of blood 
components. There is a relationship 
berween these risks and the number 
of donor exposures. The risk of 
infection is geographically variable. 
Risks listed below are per unit 
transfused. 
• Hepatitis C cints can be transmit-
ted by blood transfusion. With the 
introduction of a screening test to 
detect anti-HCV in donated 
blood, and the discarding of 
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P & T HIGHLIGHTS 
The following action were taken at the November 12, 1994 Pharmacy and 
Therapeutics Committee Meeting- Maria Barr, Pharm.D., Barbara Leri, Pharm.D., 
Richard Townsend, R.Ph. 
FORMULARY ADDITIONS 
Venlafaxine (Effexor, Wyeth-Ayerst) was 
approved for addition to the formulary. 
Venlafaxine is a bicyclic antidepressant that 
inhibits reuptake of serotonin, 
norepinephrine, and to a lesser extent, 
dopamine. Unlike the tricyclic 
antidepressants, the drug does not possess 
anticholinergic activity. Venlafaxine 
appears to have a more rapid onset of action 
than the antidepressants currently available. 
However, direct comparisons with · other 
agents are lacking and the data is limited. 
The recommended dose of Venlafaxine is 
75mg/day initially, in i or 3 divided doses. 
Titration in increments of75mg/day at 4 day 
intervals to a total of 225mg/day is 
recommended. Patients with severe 
depression may require up to 375mg/day in 
3 divided doses. The dose should be 
reduced 50% in patients with hepatic 
impairment. Dosage adjustments may be 
required in patients with renal impairment. 
For patients in hemodialysis, the dose 
should be decreased 50% and administered 
post -dialysis. 
Adverse reactions are similar to other 
selective serotonin reuptake inhibitors. 
Nausea. headache, anxiety. anorexia, 
vomiting, somnolence. sweating, dizziness, 
blurred vision, and sexual dysfunction are 
the most common during treatment with 
venlafaxine. Regular blood pressure 
monitoring is recommended for all patients. 
Dosage reduction or discontinuation of 
therapy should be considered in patients 
with a sustained increase in blood pressure. 
Venlafaxine should not be used in 
combination with monoamine oxidase 
inhibitors (MAOI) or within 14 days of 
discontinuing MAOI therapy. 
STOP ..... THE BLEEDING! 
Aprotinin (TrasylolR) was added to the 
formulary in May, 1994 for a 3 month 
evaluation. Aprotinin, a bovine derived 
protein, is approved for use in 
cardiothoracic patients who are at high risk 
of bleeding during their procedure. 
Approval of Aprotinin occurred following 
development of specific criteria for use by 
the cardiothoracic division. An evaluation 
was conducted reviewing all patients who 
received Aprotinin through 8/94. 
Additionally, a historical control group was 
selected for comparison to the Aprotinin 
patients. A total of 39 Aprotinin patients 
were compared to 18 controls. The controls 
were selected by the perfusion department 
based on type of procedure and surgeon. 
The results of the preliminary evaluation are 
listed in Table 1 on the next page: 
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Table I· APROTININ- PRELIMINARY EVALUATION RESULTS 
Control ..$_ 2 units > 2 units Study ..$.. 2 units > 2 units 
(18) · PRBC (10) PRBC (8) (38)* PRBC (19) PRBC but..$.. 
8 units 
PRBC (13) 
Ave LOS 16 15.2 17.3 14 13.8 15.7 
Ave OHU LOS 4 2.7 4.5 5 2.8 7.4 
Ave hrs until CT d/c'd 46 46.4 45.8 45 43.6 44.2 
Ave total CT drainage 1046 840 1303 1222 635 978 
post-op (ml) 
Total blood loss (ml) 1228 790 1700 1054 810 988 
Ave CPB (min) 168 119 213 185 166 170 
Ave time of procedure 326 292 368 399 353 385 
(min) 
Ave PRBC (units) 4 5 
Ave units 11 10 
Ave cost of Aprotinin N/A N/A NIA 1504 1524 1494 
($) 
Ave cost of blood 834 82 1725 959 232 1061 
products ($) 
* 1 patient was not able to be assessed; expired prior to surgery. :l pat1ents rece1ved > ~ umts PRHC. 
A total of 5 patients expired who received Aprotinin during this evaluation period. 
No conclusions can be drawn based on the 
preliminary data due to the small sample 
size of both groups as well as problems 
identified in matching the two groups. 
Trends towards shorter total lengths of stay, 
a decrease in total blood loss and possible or 
decrease in total blood products used seems 
to be evident on initial evaluation. The data 
is being forwarded to the CT division for 
review and comment. Further evaluation 
may be warranted encompassing the CT 
division's input and utilizing a more 
accurate method of matching control 
patients. 
THE LINES OF 
COMMUNICATION ARE OPEN! 
Aprotinin (TrasylolR). a medication 
approved for use in high-risk cardiothoracic 
surgery. is a bovine protein which may 
cause an antigen-antibody reaction. 
Anaphylaxis may result with repeat exposure 
and possibly even with initial exposure. 
Due to the risk of anaphylaxis, an extensive 
campaign has been instituted to prevent any 
serious adverse events specifically related to 
the allergic potential of this medication. 
Aprotinin is being addressed specifically for 
a variety of reasons. First, many health 
care professionals may be unaware of 
Aprotinin administration since it is utilized 
principally in .the operating room. 
Secondly, the patient may not be aware they 
received Aprotinin during surgery. Finally, 
though only approved for CT surgery 
presently, the potential for use of Aprotinin 
in other high risk procedures exists. This 
may place the patient at risk without proper 
education and communication of Aprotinin 
use. 
Several mechanisms of documentation have 
been initiated. The surgeon will document 
Aprotinin's use in both post-operative note 
as well as in the operative summary. The 
attending physician will be documenting 
Page 22 
) 
Aprotinin in the discharge summary. This 
will assure other institutions who care for 
the patient and receive a copy of the 
discharge summary will be made aware of 
Aprotinin administration. Anesthesia will be 
placing bright colored stickers on the front 
of the chart and in the progress notes to 
assure other staff members are informed of 
Aprotinin administration. (The stickers are 
not yet available). Once an order for 
Aprotinin is received, the pharmacy 
department will enter Aprotinin in the 
allergy section of PHAMIS. This will 
assure that if Aprotinin is ordered a second 
time or on a subsequent admission, the 
pharmacist will be alerted to inform the 
physician of previous exposure. As a 
method of insuring the patient is educated, 
a patient education sheet will be reviewed 
with the patient by the discharge nurse or 
physician. Following discharge, the patient 
will receive a wallet card stating Aprotinin 
was given to them during CT surgery with 
a cover letter to explain its purpose. 
Allergy identification information will also 
be provided to the pjlient. 
MED ERROR PREVENTION 
A medication error quality review form 
(MEQRF) is a multidisciplinary document 
developed to gather information on 
medication errors and to identify areas for 
future prevention. The pilot period has been 
completed and the form is ready for 
housewide use. The MEQRF is intended to 
be used by all disciplines. 
UNIT BASED PHARMACIST -
PATIENT FOCUSED CARE 
The seventh floor has had a pilot project 
over the past few months of having a 
pharmacist on the units to perform order 
entry, drug information consults, patient 
interviews and consults, ·and nursing 
inservices to name a few. Positive 
outcomes of the project included a decrease 
in turn around time, increased nursing 
satisfaction and acceptance of pharmacy 
intervention/ recommendations by the 
attending physicians. Results of the project 
was presented to JCAHO during the 
Performance Improvement Session. Keep 
up the good work! 
ALCOHOL - METRONIDAZOLE 
INTERACTION 
Disulfiram reactions (characterized as 
flushing, nausea, and vomiting) may occur 
when metronidazole is given concurrently 
with alcohol or alcohol-containing 
medications. This is a dose-related reaction 
with the incidence reported to be anywhere 
from 2% to 24%. 
Many oral elixirs and solutions contain a 
certain percentage of alcohol. Many health 
care providers may not be aware of 
parenteral products• that also contain alcohol. 
(See Table 2 on the next page). 
Alcohol-free and acceptable alternative 
agents can be provided for those patients on 
metronidazole experiencing a disulfiram like 
reaction. 
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Table 2: ALCOHOL CONTENT OF PARENTERAL FORMULARY MEDICATIONS 
I PARENTERAL PRODUCT 
IV TMP-Sulfa (BactrirnR) 
IV Nitroglycerin, Abbott 
IV Phenytoin (DilantinR) 
IV Diazepam (ValiumR) 
IV Pentobarbital . 
IV Ketorolac (ToradolR) 
IV Cyclosporin 
CO$T CORRECTIONS ON THE 
REVISED ANTIBIOGRAM 
It has been brought to the pharmacy's 
attention that a few daily antibiotic 
acquisition costs listed on the revised 
antibiogram had omission errors. We 
apologize for this error and would like to 
provide the corrections at this time. The 
following antibiotic costs should have been 







Please note that the Parenteral Antibiotic 
Order Sheet contains the correct daily 
acquisition costs for parenteral formulary 
antimicrobial agents. 








PEDIATRIC ANTIBIOTIC ORDER 
FORM 
The committee approved a form for use in 
prescribing antibiotics for pediatric patients. 
The form includes an area for 
documentation of the patient's weight and 
pediatric dosage guidelines for formulary 
drugs. Guidelines for commonly prescribed 
antibiotics are on the back of the page. 
Development of the form was a 
multidisciplinary effort involving the 
departments of Pharmacy, Pediatrics, and 
Infectious Disease. The form will be made 
available on all ' units where care for 
pediatric patients is provided. Indication 




Parenteral Antibiotic Guidelines for Pediatric Patients** -
DRUG AGE · INDICATION DOSAGE (Maximum Dose) 
Acyclovir Cutaneous HSV S mglkg IV q8h, infuse over I hour 
(Zovira.x) HSV Encephalitis. Varicella I 0 mg/kg IV q8h, infuse over I hour 
(45 mg/kg/day) 
Ampicillin 0-7 days Meningitis SO mg/kg IV q8h 
(Omnipen) Other SO mg/kg IV or IM ql2h 
>7 days Meningitis SO mglkg IV q6h 
Other 2S mglkg IV or IM q6h 
(400 mglkglday or 12 grams) 
Cefazolin 0-7 days 20 mglkg IV or IM q 12h 
(Ancel) >7 days 25 mglkg IV or IM q8h 
(100 mglkglday or 6 grams) 
Cefotaxime 0-7 days Meningitis SO mglkg IV or IM ql2h 
(Ciaforan) 8-30 days Meningitis SO mglkg IV or IM q8h 
>30 days Meningitis 50 mg/kg IV or IM q6h 
(300 mglkg/day or 12 grams) 
Ceftria.xone Meningitis 100 mglkg IV or IM q24h 
(Rocephin) Other SO mglkg IV or IM q24h 
(100 mglkglday or 4 grams) 
Cefuroxime 25-50 mg/kg IV or IM q8h 
(Zinacef) (300 mg/kg/day or 9 grams) 
Clindamycin 0-7 days ~ mg/kg IV or IM q8h 
(Cieocin) 8-30 days 7 mglkg IV or IM q8h 
>30 days 10 mg/kg IV or IM q8h 
(40 mglkg/day) 
Erythromycin 0-7 days 10 mglkg IV ql2h 
(Erythrocin) 8-30 days I 0 mglkg IV q8h 
>30 days I 0 mglkg IV q6h 
(. 50 mglkg/day or 4 2rams) 
Gentamicin 0-7 days 2.5 mglkg IV or IM ql2h 
(Garamycin) >7 days 2.5 mg/kg IV or IM q8h 
(Based on serum levels) 
Nafcillin 0-7 days Meningitis 50 mglkg IV or IM q8h 
(Unipen) Other 25 mglkg IV or IM q8h 
>7 days Meningitis 50 mg/kg IV or IM q6h 
Other 25 mglkg IV or IM q6h 
(200 mg/kg/day or 12 grams) 
Penicillin G 0-7 days Meningitis 50,000 units/kg IV q8h 
(Pfizerpen) Other 2~.000 units/kg IV q8h 
>7 days Meningitis 50.006 units/kg IV q6h 
Other 25,000 units/kg IV q6h 
>I year ivlen ingitis 66,500 units/kg IV q4h 
Other 50.000 units/kg IV q6h 
(500.000 units/kg/day or 24 million units/d:ly) 
Vancomycin 0-7 days 15 mglkg I\' ql2h 
(Vancocin) 8-30 days 15 mgJkg I\· q8h 
>30 days Meningitis 15 mg.•kg I\' q6h 
Other I 0 mg.•kg 1\' q6h 
(60 mg/k~/day) 
"* General dosage guidelines for pediatric patients are listed. Drug therap~· should be tailored to meet the needs of 
the patient. In special circumstances such as premature infants or patients with renal or hepatic impairment. consult 
the appropriate literature or call Clinical Pharmacy Services (17-#2797, CC-888-t) for additional information. 
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FYI- ORAL FLUCONAZOLE'S 
NEW INDICATION 
Fluconazole (DiflucanR) recently received 
FDA approval for a new indication. Single 
dose therapy with 150mg oral fluconazole is 
indicated for the treatment of vaginal 
candidiasis. It has been found to be equally 
efficacious as 7 day therapy with 
intravaginal clotrimazole or miconazole. A 
cost comparison of the OTC and Rx 
available agents are listed below. 
AGENT DOSE AND DURATION $ PER THERAPY 
Butoconazole Vaginal Cream 2% 1· applicant intra vaginally $18.35 OTC 
QHS x 3 days 
Clotrimazole Vaginal Cream 1% 1 applicant intravaginally $12.00 OTC 
QHS x 7 days 
Clotrimazole Vaginal Tablet 1 OOmg tablet intra vaginally $12.85 OTC 
QHS x 7 days 
Clotrirnazole Vaginal Tablet 500mg tablet intravaginally x $12.71 Rx 
one~ 
Miconazole Vaginal Cream 2% 1 applicant intravaginally $12.85 OTC 
QHS x 7 days ; 
Miconazole Vaginal Suppository 1 OOmg suppository $12.85 OTC 
intravaginally QHS x 7 days 
Miconazole Vaginal Suppository 200mg suppository $23.22 Rx 
intravaginally QHS x 3 days 
Nystatin Vaginal Tablet 1 tablet intravaginally QHS x $6.44 Rx 
14 days 
Terconazole Vaginal Cream 0.4% 1 applicant intravaginally $22.26 Rx 
QHS x 7 days 
I 
$22.26 Terconazole Vaginal Suppository 80mg vaginal suppository Rx 
QHS x 3 days 
Fluconazole 150mg single oral dose $10.62 Rx 
Single dose oral therapy with fluconazole 
offers a more convenient method for treating 
vaginal candidiasis. Commonly reported 
adverse e~··.:cts include nausea. vomiting. 
diarrhea ... ~·,Jominal pain and headache. 
Anaphylactiod reactions have been reported 
with single doses. The impact of single 
dose fluconazole use on Candida resistanct: 
patterns is not know at this time. 
pl.lll~94.hi 
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CRITERiA FOR RECOMMENDATION FOR APPOINTMENT TO THE 
PENNSYLV AN1A STATE UNIVERSITY FACULTY 
1. Attending and Professional staff of the Lehigh Valley Hospital (L VH) may be considered 
for appointment to the Pennsylvania State University (PSU) faculty. 
2. Appointment to the PSU faculty will be the only university faculty appoiQ.tment held by 
the faculty member, except for adjunct or honorary appointments at other universities. 
3. Appointment Process: 
a. The appointment of Clinical Assistant Professor will be made by PSU 
upon recommendation of L VH. This will be the standard appointment for 
L VH attending physicians. 
b. Advanced level appointments will require review of the application by the 
L VH Faculty Appointments Committee and the PSU Faculty Affairs 
Committee. 
4. Pennsylvania State University has three categories for academic rank: 
a. Clinical [PrefiXed]: Title indicates primary involvement in patient care 
with teaching as a secondary commitment. The majority of affiliate 
hospital (L VH) appointments will be in this category. 
b. Clinical-Educator[SufrJXed Clinical]: Title indicates evidence of 
scholarly productivity in addition to patient care and teaching. Some L VH 
appointments will be in this category. 
c. Scientist-Educator [Unmodified]: Title indicates involvement in scholarly 
patient care related activities including clinical or basic research and 
appropriate scholarly publications. Only a few L VH appointments will be 
in this category. Demonstrated academic leadership is required. 
5. General Criteria for all Academic Appointments: 
Note: Not every faculty member should be expected to demonstrate excellence in 
each criterion. However, for all appointments, teaching ability and effectiveness 
at L VH will be a prime consideration. 
a. Teaching ability and effectiveness; 
1. Commitment to student teaching; 
ii. Commitment to resident teaching; 
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iii. Adequate student/resident evaluations of teaching; 
1v. Recommendations from previous employment of teaching 
effectiveness; 
v. Awards, prizes or certificates acknowledging teaching 
effectiveness, skills or innovation; 
b. Research and/or creative accomplishments; 
i. Publication in peer reviewed journals; 
11. Non-research publications such as book chapters, books (including 
editorship), computerized instruction and teaching materials related 
to field or specialty; 
m. Grants or awards for basic, clinical, applied or outcomes-based 
research; 
c. Scholarship and mastery of subject matter; 
i. Appropriate discipline Board diplomate; 
u. Journal reviewer or editor; 
111. Participation in regional or national organizations, including study 
sections; 
iv. Invitation to speak at other institutions; 
d. Patient Care (where applicable); 
1. Member of active medical staff, without restriction; 
n. Recognition by peers of superior clinical skills; 
e. Service to the Hospital and the public in the profession; 
i. Participation in CME education as faculty; 
n. Service on hospital committees of appointed positions; 
iii. Service in the administrative aspects of the teaching program for 
students or residents. 
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6. Criteria for Advanced Prefixed Academic Appointment: 
a. Clinical Associate Professor 
i. Publication in journals, books, monographs or symposia and 
presentation at regional or national meetings; 
ii. Clinical excellence acknowledgement by peers [letters of 
recommendation]; 
111. Regional reputation [society memberships, site reviewer or 
inspector for national accrediting agency, letters of 
recommendation]; 
IV. Education demonstrated commitment to teaching, curriculum 
planning or course leadership; 
v. Service commitment as evidenced by committee membership and 
chairmanship, division and/or section leadership. 
v1. Minimum of three years at the Assistant Professor rank, or 
appropriate service at another institution or university. 
b. Clinical Professor 
1. Publication in peer reviewed journals, books, monographs or 
symposia, editorship, presentation at regional and national 
meetings; 
ii. Regional or national leadership in clinical medicine through 
acknowledgement by peers of clinical excellence [letters of 
recommendation]; 
iii. Membership in national societies, academic recognitions or 
awards; 
IV. Lead~rship in educational activities at L VH is required; 
educational endeavors at the regional or national level will also be 
considered; 
v. Commitment to hospital service functions as evidenced by 




v1. Minimum of three years at the Associate Professor rank, or 
appropriate service at another institution or university. 
7. Criteria for Advanced Clinical-Educator or Scientist-Educator: 
a. Clinical-Educator 
1. Regular publication in peer-reviewed journals; 
u. Acknowledgement by peers of clinical excellence [letters of 
recommendation]; 
iii. Regional reputation [society membership, presentation at 
regional or national meetings, site reviewer or inspector for 
research grant or national accrediting agency, letters of 
recommendation]; 
iv. Demonstrated innovative approaches to teaching and 
training, curriculum planning or course leadership; 
v. Minimum of four years at the next lower rank, or 
appropriate service at another institution or university. 
b. Scientist-Educator 
1. Regular publication in peer reviewed journals 
demonstrating continued, focused interest in one or more 
areas of scientific or medical interest; 
ii. Evidence of recognized leadership locally, regionally, and 
nationally in the chosen specialty or subspecialty; 
iii. Invitations to membership or fellowship in national 
societies, academic recognitions or awards, hospital and/or 
department leadership; 
iv. Testimony of nationally recognized practitioners in the 
same field; 
v. Minimum of four years at the next lower rank, or 
appropriate serv;<·:; at another institution or university. 




a. Prefixed Clinical appointments will be for three years; 
b. Clinical-Educator and Scientist-Educator will be for four years; 
c. L VH will notify PSU should the individual terminate his/her 
affiliation with L VH. PSU shall have the right to review and 
withdraw the appointment upon this notification. 
9. PSU guidelines will be used for definition and appointment for ranks of lecturer, 










Group Meeting Schedule 
1995 
Listed below are the dates for the P,hysician Well-Being Group meetings for 1995. All 
meetings will be held in the Cafeteria Conference Room at Lehigh Valley Hospital, 
Cedar Crest & 1-78, from 6 to 7:30 p.m., unless otherwise noted. 
Mondays Wednesdays 
January 23 January 11 - Classroom 3 
February 20 February 8 - Classroom 3 
March 20 March 8 - Classroom 4 
April 17 April 5 
May 15 May 3 - Classroom. 2 
June 12 May 31 
July 10 June 28 
August 7 July 26 
October 2 August 23 
October 30 September 20 
November 27 October 18 - Classroom 2 
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